GlobeNewswire Inc.··Chemomab Therapeutics Ltd.Chemomab Posts $1.8M Loss as Nebokitug Data Bolsters PSC Pipeline Strategy
Chemomab Therapeutics reported Q1 2026 net loss of $1.8M with $8M cash runway through Q1 2027, while advancing clinical data for nebokitug in primary sclerosing cholangitis.
CMMBclinical datastrategic partnerships